VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People

• Main Authors: Lindsay M. Henderson (Author), Renee F. Robinson (Author), Lily Ray (Author), Burhan A. Khan (Author), Tianran Li (Author), Denise A. Dillard (Author), Brian D. Schilling (Author), Mike Mosley (Author), Patricia L. Janssen (Author), Alison E. Fohner (Author), Allan E. Rettie (Author), Kenneth E. Thummel (Author), Timothy A. Thornton (Author), David L. Veenstra (Author)
• Format: Book
• Published: Wiley, 2019-05-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Alaska Native and American Indian (AN/AI) people have unique pharmacogene variation that may affect warfarin disposition and therapeutic response. We performed targeted genotyping for cytochrome P450 (CYP)2C9, vitamin K epoxide oxidase reductase complex subunit 1 (VKORC1), CYP4F2, CYP4F11, and gamma...